Sanofi is reported to be preparing a move to take control of US biotech Ocular Therapeutix, after an initial bid was rejected last year. That is according to French newspaper La Lettre, which said ...

OCUL is trading near the bottom of its 52-week range and below its 200-day simple moving average. Price change The price of OCUL shares has decreased $0.17 since the market last closed. This is a 1.91 ...

OCUL is trading in the middle of its 52-week range and below its 200-day simple moving average. Price change The price of OCUL shares has increased $0.71 since the market last closed. This is a 8.01% ...

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes ...

As of October 23 at 11:30:00 p.m. UTC. Market Open. A ratio that indicates liquidity. Higher ratios suggest the asset is more actively traded and easier to buy/sell near its true value. Lower ratios ...